Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here is one profitable company that leverages its financial strength to beat the competition and two that may face some trouble.
Two Stocks to Sell:
Warner Bros. Discovery (WBD)
Trailing 12-Month GAAP Operating Margin: 2%
Formed from the merger of WarnerMedia and Discovery, Warner Bros. Discovery (NASDAQ: WBD) is a multinational media and entertainment company, offering television networks, streaming services, and film and television production.
Why Is WBD Risky?
- Annual sales declines of 5% for the past two years show its products and services struggled to connect with the market
- Free cash flow margin is anticipated to expand by 1.5 percentage points over the next year, providing additional flexibility for investments and share buybacks/dividends
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
At $27.01 per share, Warner Bros. Discovery trades at 11.1x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than WBD.
Chemed (CHE)
Trailing 12-Month GAAP Operating Margin: 13.4%
With a unique business model combining end-of-life care and household services, Chemed (NYSE: CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.
Why Does CHE Give Us Pause?
- 4% annual revenue growth over the last five years was slower than its healthcare peers
- Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 3.6% annually
- Eroding returns on capital suggest its historical profit centers are aging
Chemed’s stock price of $368.68 implies a valuation ratio of 15.6x forward P/E. Check out our free in-depth research report to learn more about why CHE doesn’t pass our bar.
One Stock to Buy:
Stride (LRN)
Trailing 12-Month GAAP Operating Margin: 16%
Formerly known as K12, Stride (NYSE: LRN) is an education technology company providing education solutions through digital platforms.
Why Will LRN Beat the Market?
- Market share has increased this cycle as its 14.6% annual revenue growth over the last five years was exceptional
- Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 45% annually
- Improving returns on capital reflect management’s ability to monetize investments
Stride is trading at $85.00 per share, or 10.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
